Latest Ratios: P/E Ratio -4.1x · EV/EBITDA N/A · ROE N/A. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $59M | $48M | $27M | $37M | $88M | $149M | — | — |
| Enterprise Value | $-13295826139 | $-13307550056 | $27M | $33M | $68M | $110M | — | — |
| P/E Ratio → | -4.06 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | 6.28 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 100.0% |
| Operating Margin | — | — | — | — | — | — | — | -3231.4% |
| Net Profit Margin | — | — | — | — | — | — | — | -3451.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -239.5% | -127.1% | — | — |
| ROA | -125.2% | -125.2% | -210.0% | -172.6% | -90.7% | -134.9% | -553.8% | -1818.5% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -1034.2% | -1034.2% | — | -2365.3% | -190.1% | -263.7% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | -1.64 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -110.50 | -11.42 | -5.65 | -14.25 |
Net cash position: cash ($13.4B) exceeds total debt ($5M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.06 | 1.06 | 0.72 | 0.32 | 1.61 | 2.41 | 0.25 | 0.12 |
| Quick Ratio | 1.06 | 1.06 | 0.72 | 0.32 | 1.61 | 2.41 | 0.25 | 0.11 |
| Cash Ratio | 1025.24 | 1025.24 | 0.66 | 0.30 | 1.55 | 2.36 | 0.19 | 0.04 |
| Asset Turnover | — | — | — | — | — | — | — | 0.53 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | 278.40 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 1.3% | 0.2% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 1.3% | 0.2% | 0.0% | — | — |
| Shares Outstanding | — | $4M | $4M | $3M | $3M | $3M | $3M | $2M |
Clinical stage liquidity dependence
As reported in financial statements, the company's current ratio has exhibited extreme volatility, ranging from 0.15 to 1.38 over the last ten quarters, which suggests that the firm's ability to meet short-term obligations is entirely dependent on the timing of external capital infusions rather than operational cash generation.
The erratic nature of the current ratio indicates a lack of stable working capital management, which is typical for a pre-revenue biotech but nonetheless presents a high risk of insolvency. Investors should monitor the company's ability to maintain a current ratio above 1.0, as any dip below this threshold may necessitate dilutive financing to sustain clinical operations.
Based on reported figures, the company's days payable outstanding has fluctuated wildly between 4,086 and 8,505 days, a trend that appears to reflect highly irregular vendor payment cycles and suggests significant instability in the firm's management of its accounts payable and broader working capital requirements.
Such extreme variance in DPO metrics implies that the company may be stretching its payment terms to preserve cash, which could potentially strain relationships with critical clinical trial vendors. This lack of consistency in working capital management warrants further investigation into whether these figures are driven by operational necessity or accounting adjustments related to parent-company service agreements.
According to recent SEC filings, MiNK's financial profile, characterized by a persistent negative return on assets and lack of revenue, mirrors the struggles of peers like TScan Therapeutics, yet the company's reliance on Agenus for infrastructure creates a unique structural dependency that is absent in more independent biotech entities.
When compared to peers like Fate Therapeutics, MiNK appears to lack the scale necessary to achieve operational efficiencies, leaving it more vulnerable to sector-wide funding downturns. The gap between MiNK and its peers is likely structural, as the company's reliance on donor-derived cells may prove less scalable than the iPSC-based platforms utilized by larger competitors.
As noted in the provided financial data, the use of the current ratio to assess MiNK's solvency is fundamentally flawed because it fails to account for the company's lack of recurring revenue and its extreme sensitivity to the timing of equity-linked financing and parent-company intercompany allocations.
Investors should instead focus on the 'cash burn rate' and 'runway in months' as more accurate indicators of financial health, as traditional liquidity ratios obscure the reality that the company has no operational cash flow to support its balance sheet. Relying on the current ratio may lead to a false sense of security regarding the firm's ability to sustain its clinical pipeline.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying INKT stock.
MiNK Therapeutics, Inc.'s current P/E ratio is -4.1x. This places it at the 50th percentile of its historical range.
Based on historical data, MiNK Therapeutics, Inc. is trading at a P/E of -4.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.